Implications of the prostate cancer prevention trial: A decision analysis model of survival outcomes

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1911-1920

  Lotan, Yair ^a   Cadeddu, Jeffrey A ^a   Lee, J Jack ^a   Roehrborn, Claus G ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO; ENZYME INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GLEASON SCORE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; THEORETICAL MODEL; TREATMENT OUTCOME; TUMOR BIOPSY; DECISION TREE; INCIDENCE; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

AGED; DECISION TREES; ENZYME INHIBITORS; FINASTERIDE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 15744371131     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.137     Document Type: Article

References (26)

1. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224, 2003
2. White CC, Koplan JP, Orenstein WA: Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 75:739-744, 1985
3. Eddy DM: Screening for cervical cancer. Ann Intern Med 113:214-226, 1990
4. Hershman D, Sundararajan V, Jacobson JS, et al: Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis. J Clin Oncol 20:9-16, 2002
5. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975-980, 1998
6. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994
7. Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248, 1994
8. Gerber GS, Thisted RA, Scardino PT, et al: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276: 615-619, 1996
9. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001
10. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
11. Andriole GL, Guess HA, Epstein JI, et al: Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial-PLESS Study Group, Proscar Long-term Efficacy and Safety Study. Urology 52:195-202, 1998
12. Civantos F, Watson RB, Pinto JE, et al: Finasteride effect on prostatic hyperplasia and prostate cancer: A comparative clinicopathologic study of radical prostatectomies. J Urol Path 6:1-13, 1997
13. Stephenson RA: Prostate cancer trends in the era of prostate-specific antigen: An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 29:173-181, 2002
14. Scardino PT: The prevention of prostate cancer: The dilemma continues. N Engl J Med 349:297-299, 2003
15. Smith DS, Humphrey PA, Catalona WJ: The early detection of prostate carcinoma with prostate specific antigen: The Washington University experience. Cancer 80:1852-1856, 1997
16. Hoedemaeker RF, van der Kwast TH, Boer R, et al: Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 93:1153-1158, 2001
17. Catalona WJ, Antenor JA, Roehl KA, et al: Screening for prostate cancer in high risk populations. J Urol 168:1980-1984, 2002
18. Catalona WJ, Ramos CG, Carvalhal GF, et al: Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 55:791-795, 2000
19. Wright JC, Weinstein MC: Gains in life expectancy from medical interventions: Standardizing data on outcomes. N Engl J Med 339:380-386, 1998
20. Hatziandreu EI, Koplan JP, Weinstein MC, et al: A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health 78:1417-1421, 1988
21. Tsevat J, Weinstein MC, Williams LW, et al: Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 83:1194-1201, 1991
22. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
23. Grann VR, Sundararajan V, Jacobson JS, et al: Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J 6:169-178, 2000
24. Yang XJ, Lecksell K, Short K, et al: Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group: Proscar Long-Term Efficacy and Safety Study. Urology 53:696-700, 1999
25. Algaba F, Epstein JI, Aldape HC, et al: Assessment of prostate carcinoma in core needle biopsy: Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 78:376-381, 1996
26. Partin AW, Mangold LA, Lamm DM, et al: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58:843-848, 2001